🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations!!

The inspiring Jill Feldman gives an #ERAS tour of significant progress in #lungcancer advocacy over the past 20+ yrs, w/ patient-caregiver groups playing a critical role in expanding funding & demanding a voice at the table, “making sure trials are designed with us, not for us.”

🫁 KRAS mutations in aNSCLC 🫁 ⭐️Developmental therapeutics list of KRAS inhibitors. KRASKickers #LCSM #NSCLC x.gd/WBdxF

PET surveillance in NSCLC after definitive therapy JTO & JTO CRR. SUPE_R trial randomized 750pts to PET/CT or CT alone. PET increased detection of recurrence, but no difference in those treated with curative intent (48%); no difference in survival (HR 0.97) jto.org/article/S1556-…

Do I need to Know my cancer mutation? Live Tomorrow: kraskickers.org/event-details/…

Only for KRAS patients & care partners, KRAS Kickers is all about empowering you to #KickCancersKRAS #Hope

Having cancer is the diagnosis. What does a patient need to know about biomarkers? Replay at your leisure: youtu.be/DdKPFYQg7eI?si…

Updates in cancer Research #AACR25 Chicago The best is yet to come …

Congratulations to Sandra Misale, PhD, recipient of the 2025 Cancer Discovery Early Career Award, which recognizes the outstanding contributions of #earlycareer investigators. Learn more: brnw.ch/21wSfdp #AACR25 Johns Hopkins Medicine Johns Hopkins Kimmel Cancer Center AACR

Zoldonrasib (mutant selective covalent inhibitor targeting the ‘ON’ state of RAS G12D. Most patients were PDAC but included NSCLC. #AACR25 KRASKickers AACR #lcsm

Specifically looking at #lcsm with zoldonrasib 1200 mg daily ORR=61% (n=11/18) KRASKickers #AACR25 #lcam AACR

Ph1 trial of zoldonrasib (RMC-9805), an oral KRAS G12D inhibitor in pts w/ #NSCLC showed ORR of 61%. Side effects primarily gastro-intestinal. Great to see new options for this pt group. Kathryn C. Arbour Memorial Sloan Kettering Cancer Center #AACR25 KRASKickers

So proud of you & the #KickKRAS progress you’re making!! KRASKickers

Thanks, Jill Feldman , for reminding us living longer doesn't mean living better! W/ new treatments, pts w/ advanced #lungcancer are living longer. How to balance tx decisions w/ quantity vs. quality of life? Measuring what matters is IMP -> Survivorship matters! #AACR25

Another great talk about the patient experience and what is/is not tolerable… Jill Feldman #AACR25 #AACRSSP

If we aren’t measuring what matters, we aren’t just missing data - we are missing the point! #AACR25 #LCSM

Dr. Patrick Forde summarizes perioperative chemo-immunotherapy for resectable NSCLC at #RomeLung25. Ongoing debate regarding the value of the adjuvant component. Who derives benefit? Non-PCR? PD-L1 negative? Will MRD assays help guide us?

67% ORR in KRAS G12C+ NSCLC! 30% if TKI pretreated. Have always believed the first gen TKIs were just proof of principle and the really impactful drugs would come next, looks like that could be happening. #LCSM KRASKickers

Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer - Journal of Thoracic Oncology jto.org/article/S1556-… JTO & JTO CRR

KRAS #Cancer Clinical Trial Updates: What #Patients Need to Know from #ASCO ... Marina Garassino #lungcancer #G12C TerriConneran youtu.be/FT3yNIUYRqA?si…